Logo image of HROW

HARROW INC (HROW) Stock Overview

NASDAQ:HROW - US4158581094 - Common Stock

39 USD
+0.01 (+0.03%)
Last: 8/29/2025, 8:00:01 PM
39.45 USD
+0.45 (+1.15%)
After Hours: 8/29/2025, 8:00:01 PM

HROW Key Statistics, Chart & Performance

Key Statistics
52 Week High59.23
52 Week Low20.85
Market Cap1.44B
Shares37.00M
Float31.18M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.25
PEN/A
Fwd PE20.99
Earnings (Next)11-11 2025-11-11/amc
IPO02-08 2013-02-08
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


HROW short term performance overview.The bars show the price performance of HROW in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

HROW long term performance overview.The bars show the price performance of HROW in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300

The current stock price of HROW is 39 USD. In the past month the price increased by 24.88%. In the past year, price decreased by -3.61%.

HARROW INC / HROW Daily stock chart

HROW Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.36 693.36B
JNJ JOHNSON & JOHNSON 17.72 426.69B
NVO NOVO-NORDISK A/S-SPONS ADR 14.48 250.88B
AZN ASTRAZENECA PLC-SPONS ADR 18 247.73B
NVS NOVARTIS AG-SPONSORED ADR 14.3 244.98B
MRK MERCK & CO. INC. 10.92 210.11B
PFE PFIZER INC 7.3 140.77B
SNY SANOFI-ADR 11.17 120.68B
BMY BRISTOL-MYERS SQUIBB CO 7.01 96.03B
GSK GSK PLC-SPON ADR 8.8 79.92B
ZTS ZOETIS INC 25.14 69.31B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.69 47.34B

About HROW

Company Profile

HROW logo image Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Company Info

HARROW INC

1A Burton Hills Blvd, Suite 200

Nashville TENNESSEE 37205 US

CEO: Mark L. Baum

Employees: 382

HROW Company Website

HROW Investor Relations

Phone: 16157334731

HARROW INC / HROW FAQ

What is the stock price of HARROW INC today?

The current stock price of HROW is 39 USD. The price increased by 0.03% in the last trading session.


What is the ticker symbol for HARROW INC stock?

The exchange symbol of HARROW INC is HROW and it is listed on the Nasdaq exchange.


On which exchange is HROW stock listed?

HROW stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for HARROW INC stock?

14 analysts have analysed HROW and the average price target is 61.03 USD. This implies a price increase of 56.47% is expected in the next year compared to the current price of 39. Check the HARROW INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HARROW INC worth?

HARROW INC (HROW) has a market capitalization of 1.44B USD. This makes HROW a Small Cap stock.


How many employees does HARROW INC have?

HARROW INC (HROW) currently has 382 employees.


What are the support and resistance levels for HARROW INC (HROW) stock?

HARROW INC (HROW) has a support level at 38.99 and a resistance level at 39.13. Check the full technical report for a detailed analysis of HROW support and resistance levels.


Is HARROW INC (HROW) expected to grow?

The Revenue of HARROW INC (HROW) is expected to grow by 46.72% in the next year. Check the estimates tab for more information on the HROW EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy HARROW INC (HROW) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HARROW INC (HROW) stock pay dividends?

HROW does not pay a dividend.


When does HARROW INC (HROW) report earnings?

HARROW INC (HROW) will report earnings on 2025-11-11, after the market close.


What is the Price/Earnings (PE) ratio of HARROW INC (HROW)?

HARROW INC (HROW) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).


What is the Short Interest ratio of HARROW INC (HROW) stock?

The outstanding short interest for HARROW INC (HROW) is 14.44% of its float. Check the ownership tab for more information on the HROW short interest.


HROW Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to HROW. When comparing the yearly performance of all stocks, HROW is one of the better performing stocks in the market, outperforming 78.35% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HROW Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to HROW. There are concerns on the financial health of HROW while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HROW Financial Highlights

Over the last trailing twelve months HROW reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 73.4% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -2.96%
ROE -20.6%
Debt/Equity 0.78
Chartmill High Growth Momentum
EPS Q2Q%172.22%
Sales Q2Q%30.25%
EPS 1Y (TTM)73.4%
Revenue 1Y (TTM)47.69%

HROW Forecast & Estimates

14 analysts have analysed HROW and the average price target is 61.03 USD. This implies a price increase of 56.47% is expected in the next year compared to the current price of 39.

For the next year, analysts expect an EPS growth of 182.3% and a revenue growth 46.72% for HROW


Analysts
Analysts85.71
Price Target61.03 (56.49%)
EPS Next Y182.3%
Revenue Next Year46.72%

HROW Ownership

Ownership
Inst Owners57.33%
Ins Owners15.85%
Short Float %14.44%
Short Ratio8.84